ADAPTABLE patient reported item set [ADAPTABLE] 89070-7
LOINC Code
LOINC code | 89070-7 | ||||||
---|---|---|---|---|---|---|---|
name | ADAPTABLE patient reported item set [ADAPTABLE] | ||||||
description | ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness) aims to identify the optimal dose of aspirin therapy for secondary prevention in atherosclerotic cardiovascular disease. The set of patient report items is part of a project to develop, pilot and evaluate methods to validate and integrate patient-reported information with data obtained from the EHR in the context of the ADAPTABLE. | ||||||
status | ACTIVE | ||||||
Fully-Specified Name | |||||||
component | ADAPTABLE patient reported item set | ||||||
property | - | ||||||
time | Pt = Point in time: To identify measures at a point in time. This is a synonym for “spot” or “random” as applied to urine measurements. | ||||||
system | ^Patient | ||||||
scale | - | ||||||
method | ADAPTABLE | ||||||
Additional Names | |||||||
short name | |||||||
Basic Attributes | |||||||
class | PANEL.SURVEY.GNHLTH | ||||||
type | 4 Surveys | ||||||
order vs. observation | Order | ||||||
Panel Components | |||||||
| |||||||
Associated Observations | |||||||
LOINC codes that represent optional associated observation(s) for a clinical observation or laboratory test. A LOINC term may represent a single associated observation or panel containing several associated observations. | |||||||
History/Usage | |||||||
first released | |||||||
last updated | 2.71 | ||||||
last change type | MIN - change to field other than name | ||||||
Related Names | |||||||
|
Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © 1995-2024, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://loinc.org/license for the full LOINC copyright and license.
Thank you for choosing Find-A-Code, please Sign In to remove ads.